Hemophilia B is an X-linked recessive hemorrhagic disorder caused by a deficiency or abnormality of clotting factor IX. Human factor IX is a vitamin-K-dependent multidomain glycoprotein composed ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no ...

Novo Nordisk has filed its long-acting factor IX, nonacog beta pegol in the US for haemophilia B. Nonacog beta pegol is a glycopegylated recombinant factor IX with a longer half-life, developed ...

Fidanacogene elaparvovec was approved by the FDA last year for adult men with moderate to severe hemophilia B currently treated with prophylactic factor IX, who have a history of life-threatening ...

Coagulation Factor IX (human) 500 IU, 1000 IU, 1500 IU; per vial; lyophilized concentrate for IV infusion after reconstitution; contains non-therapeutic Factor II, Factor VII, Factor X.